Trial Profile
Phase 1 trial of Acamprosate/baclofen (PXT-864) in patients with Amyotrophic Lateral Sclerosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Feb 2016
Price :
$35
*
At a glance
- Drugs Acamprosate/baclofen (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Pharnext
- 18 Feb 2016 New trial record